Physician profile
Jonathan Katz
NPI 1447678487
$10,202.05
in general payments reported to CMS, 2019-2025
27 companies · $1,140 in 2025
The $1,140 reported for 2025 was more than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $445 · 2020: $552 · 2021: $1,029 · 2022: $1,360 · 2023: $1,465 · 2024: $4,211 · 2025: $1,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,958 · Consulting Fee: $2,858.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,957.83 |
| Consulting Fee | $2,858.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $3,671.60 | 2019-2025 | Idose, Idosetr, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Sight Sciences, INC. | $1,587.94 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Alcon Vision LLC | $1,138.25 | 2022-2025 | Hydrus Microstent, Rocklatan, Clareon |
| New World Medical,INC. | $618.52 | 2023-2025 | Via360, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Alcon Research LLC | $558.00 | 2024 | Hydrus Microstent |
| Abbvie INC. | $537.30 | 2022-2025 | |
| Notal Vision, INC. | $443.79 | 2021 | |
| Aerie Pharmaceuticals, INC. | $299.74 | 2020-2021 | |
| Allergan, INC. | $273.30 | 2020-2022 | |
| Trice Medical, INC. | $218.73 | 2019 | |
| Bausch & Lomb Americas INC. | $120.50 | 2022-2023 | Vyzulta, Envista Mx60 Iol |
| Acumed LLC | $109.73 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $105.01 | 2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $74.27 | 2019-2021 | |
| Eyepoint US, INC. | $73.20 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $71.81 | 2022-2024 | Tyrvaya, Ryzumvi |
| Thea Pharma INC. | $60.63 | 2023 | Iyuzeh |
| Omeros Corporation | $50.99 | 2020-2021 | |
| Dompe US, INC. | $30.56 | 2025 | Oxervate |
| Apellis Pharmaceuticals, INC. | $30.13 | 2024 | Syfovre |
| Rayner Intraocular Lenses Limited | $26.61 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Harrow Eye, LLC | $17.33 | 2025 | Triesence |
| Sun Pharmaceutical Industries INC. | $17.30 | 2020 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Novartis Pharmaceuticals Corporation | $16.16 | 2020 | |
| Ocular Therapeutix, INC. | $14.01 | 2023 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.